Zhou Zhaoyue, Zhang Yue, Li Yue, Jiang Cong, Wu Yang, Shang Lingmin, Huang Yuanxi, Cheng Shaoqiang
Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Front Oncol. 2023 Jan 4;12:1080054. doi: 10.3389/fonc.2022.1080054. eCollection 2022.
To investigate the impact of metabolic syndrome (MetS) on pathologic complete response (pCR) and clinical outcomes in breast cancer (BC) patients who received neoadjuvant chemotherapy (NAC).
We analyzed 221 female BC patients at Harbin Medical University Cancer Hospital who received NAC and divided them into MetS and non-MetS groups according to National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) criteria to investigate the association between MetS and clinicopathological characteristics, pathologic response, and long-term survival and to observe the changes in metabolic parameters after NAC.
A total of 53 (24.0%) BC patients achieved pCR after NAC in our study. MetS status was an independent predictor of pCR, and pCR was more difficult to obtain in the MetS group than the non-MetS group (P=0.028). All metabolic parameters deteriorated significantly after NAC, especially the blood lipid index (P<0.010). The median follow-up time was 6 years. After adjusting for other prognostic factors, MetS was found to be strongly associated with an increased risk of recurrence (P=0.007) and mortality (P=0.004) in BC patients receiving NAC. Compared to individuals without any MetS component, the risk of death and disease progression increased sharply as the number of MetS components increased.
In BC patients who received NAC, MetS was associated with poor outcomes, including a lower pCR rate and increased risks of recurrence and mortality.
探讨代谢综合征（MetS）对接受新辅助化疗（NAC）的乳腺癌（BC）患者病理完全缓解（pCR）及临床结局的影响。
我们分析了哈尔滨医科大学附属肿瘤医院221例接受NAC的女性BC患者，并根据美国国家胆固醇教育计划成人治疗组第三次报告（NCEP-ATP III）标准将其分为MetS组和非MetS组，以研究MetS与临床病理特征、病理反应及长期生存之间的关联，并观察NAC后代谢参数的变化。
在我们的研究中，共有53例（24.0%）BC患者在NAC后达到pCR。MetS状态是pCR的独立预测因素，MetS组比非MetS组更难获得pCR（P=0.028）。NAC后所有代谢参数均显著恶化，尤其是血脂指标（P<0.010）。中位随访时间为6年。在调整其他预后因素后，发现MetS与接受NAC的BC患者复发风险增加（P=）和死亡率增加（P=0.004）密切相关。与没有任何MetS组分的个体相比，随着MetS组分数量的增加，死亡和疾病进展的风险急剧增加。
在接受NAC的BC患者中，MetS与不良结局相关，包括较低的pCR率以及复发和死亡风险增加。
